Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients

In a meta-analysis of 10 randomized controlled trials involving 29,325 patients, treatment with glucagon-like peptide-1 receptor agonists significantly reduced major adverse cardiovascular events.

• GLP-1 receptor agonists were associated with a 21% reduction in major adverse cardiovascular events compared to placebo.
• The treatment group experienced a 20% reduction in all-cause death and a 28% reduction in myocardial infarction.
• Revascularization procedures were reduced by 24% in the GLP-1 RA group compared to placebo.
• No significant differences were observed in cardiovascular death or stroke between the two groups.
• Total adverse events, particularly gastrointestinal and gallbladder-related disorders, were higher in patients receiving GLP-1 RAs.

AI simplified